Melanie_Matheu.jpg

Kevin Chapman, PhD

Chief Scientific Officer

With more than 30 years of experience, Kevin Chapman is an avid drug hunter, life-science technologist, and entrepreneur. Kevin’s areas of expertise encompass small molecule, protein, and cellular therapeutics, diagnostics, and medical devices, with a focus on application of disruptive technologies to these fields. Kevin spent 20 years at Merck & Co., Inc. in various executive roles, and 9 years at Berkeley Lights, where he was Chief Scientific Officer.

Current areas of interest to Kevin include: enabling technologies that can be applied to human health, synthetic biology, multi-specific protein therapeutics, cell therapies, regenerative medicine, default mode network pharmacology, oncology and highly resistant and emerging pathogens.